Dysport
Dysport is a major botulinum toxin type A brand associated with Ipsen, with Galderma holding aesthetic commercialization rights in licensed territories including the United States. Its nonproprietary name is abobotulinumtoxinA.
Dysport’s potency units are specific to its preparation and assay and cannot be converted into units of other botulinum toxin products. Larger numeric amounts do not establish greater strength. (Dysport U.S. prescribing information, section 5.2 🔗)
Who Makes Dysport?
Section titled “Who Makes Dysport?”Ipsen Biopharm Ltd. in Wrexham, United Kingdom, manufactures Dysport, as identified in the Dysport prescribing information on DailyMed 🔗. Galderma commercializes aesthetic Dysport under territory-specific agreements; the U.S. and Canadian distribution rights date to the 2014 partnership expansion. Ipsen manufactures and supplies the product to Galderma. (Ipsen 2025 Universal Registration Document, section 1.2.2.2 🔗)
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Dysport |
| Nonproprietary name | AbobotulinumtoxinA |
| Toxin type | Botulinum toxin type A |
| Product origin | Ipsen |
| Manufacturer | Ipsen Biopharm Ltd., Wrexham, United Kingdom (Dysport U.S. label 🔗) |
| Aesthetic commercialization | Galderma in licensed territories (Ipsen partnership disclosures 🔗) |
Formulation And Related Products
Section titled “Formulation And Related Products”The U.S. label describes Dysport as a freeze-dried powder in single-dose vials requiring reconstitution before use. It is not the same product as Galderma’s ready-to-use liquid Relfydess, which contains relabotulinumtoxinA. (Dysport U.S. label, section 3 🔗; Medsafe Relfydess data sheet 🔗)
Azzalure and Alluzience belong to the Ipsen–Galderma aesthetic partnership alongside Dysport. Shared commercial relationships do not make the brands one global presentation or label. In its January 21, 2026 arbitration update, Galderma said termination of the early-stage R&D partnership did not affect commercialization of its existing neuromodulator portfolio. (Galderma partnership update 🔗)
Label Context
Section titled “Label Context”FDA approved Dysport on April 29, 2009 for cervical dystonia and glabellar lines (FDA original approval letter 🔗). Its current U.S. scope also includes spasticity.
The Dysport prescribing information 🔗 defines three indication groups:
| U.S. indication | Patient limits |
|---|---|
| Cervical dystonia | Adults |
| Temporary improvement of moderate to severe glabellar lines associated with procerus and corrugator muscle activity | Adults younger than 65 years |
| Spasticity | Patients 2 years of age and older |
Dysport’s U.S. aesthetic indication does not include lateral canthal lines, forehead lines, or platysma bands. The U.S. FDA indication matrix separates those treatment areas across products without implying equivalent units or dosing.
Regional availability also matters. A Dysport claim supported in one country or product-information document should not be copied into another market without checking the local label.
Migraine Development: Trial Results Are Not Approval
Section titled “Migraine Development: Trial Results Are Not Approval”On July 9, 2026, Ipsen announced positive topline results from E-BEOND and C-BEOND, phase III trials evaluating prevention of episodic and chronic migraine in adults. Both met their primary endpoint: change in monthly migraine days at week 24, measured over weeks 21–24, versus placebo. These were placebo-controlled findings, not a comparison establishing superiority over another toxin. (Ipsen BEOND results announcement 🔗)
In its October 22, 2026 results, Ipsen said migraine regulatory submissions were underway. That statement does not establish FDA acceptance or approval for migraine. Migraine is not an indication in the cited U.S. Dysport label. (Ipsen third-quarter development update 🔗; Dysport U.S. label 🔗)
Porton Down Development History
Section titled “Porton Down Development History”Dysport’s history runs through the Centre for Applied Microbiology and Research at Porton Down, where a UK therapeutic botulinum toxin preparation was developed and produced for clinical research. A peer-reviewed history of abobotulinumtoxinA 🔗 traces the later path through Porton International and successor companies. Peter Hambleton, Ph.D. represents the upstream scientific and production stage.
The later commercial pathway involved Porton International and successor companies before the product entered the current Ipsen structure. This history explains Dysport’s origin; it does not replace current manufacturer, approval, label, or Galderma commercialization information.
Market Interpretation
Section titled “Market Interpretation”Dysport is a durable comparison point because it sits beside Botox and Xeomin in many professional and consumer discussions. It is not directly interchangeable with those brands: type A products can share broad biology while differing in formulation, labeling, unit language, and market position.
Galderma’s aesthetic commercialization role also has a current leadership dimension. Flemming Ørnskov connects Galderma’s company strategy to Dysport commercialization and the separate development of Relfydess. That portfolio context does not change Ipsen Biopharm’s manufacturing role or Dysport’s product-specific label.

